Shukra Pharmaceuticals begins direct listing on NSE from 14 Aug 2026

Capital Market Events View source PDF Explain this filing

SHUKRAPHAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

—Next day

—

prior close

₹40.18

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%—

Pharmaceuticals peers, median of 167sector-0.4%—

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.9

15m

+0.9

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

—+0.1—-0.4—

Next day

—+0.2—-0.4—

—+0.6—-0.5—

—-0.0—-1.4—

—+0.5—-0.9—

—+0.8—-0.4—

—+0.6—-0.9—

15d

—+1.3—+0.0—

—-1.4—-0.1—

—-0.6—-2.8—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shukra Pharmaceuticals (BSE: 524632) has been approved for direct listing on NSE main board, with trading starting 14 August 2026 under symbol SHUKRAPHAR. The company will continue trading on BSE, making it dual-listed. Base reference price is derived from the BSE closing price on 13 August 2026. The move aims to expand visibility, attract institutional and retail investors, and improve liquidity. Ahmedabad-based firm manufactures generic formulations including tablets, capsules, and liquid injections for domestic and international markets.

Likely market impact

Dual listing on NSE may boost liquidity and attract more investors. No new shares issued; existing BSE holders get NSE access too.